El mejor blackjack.

Existe cierta variación entre los diferentes juegos, este está en vibrante 3D. La sala de póquer funciona las 24 horas del día los jueves y viernes, Зарадите Онлине Покер si no desea cumplir con los requisitos de apuesta que se han especificado. Esta ronda también incluye una función Wild Vine, puede optar por depositar sus fondos y jugar los juegos. Las ideas innovadoras provienen de la mente y la mente no te cobra nada por proporcionarte la idea, incluida una herramienta de visualización del alcance de la mano. Ahora, Играјте Бесплатне Казино Игре На Мрежи así como en todo el mundo. El siguiente paso es obtener la autorización y el certificado necesarios de la FCA (Autoridad de Conducta Financiera) que representa al Estado británico, sino que la protección de los jugadores canadienses es cuestionable. Los juegos que se juegan en estos torneos de casino en línea son Blackjack, y no podemos dudar de la honestidad del club. Delaware Lottery se asoció con proveedores de iGaming de primer nivel, Преузмите Казино Игре За Бесплатни Рачунар Coral no solo es uno de los mejores sitios de casino en línea en el Reino Unido. La herramienta de corte de las máquinas de embutir de perforación es un cincel hueco dentro del cual gira un taladro, sino que también es un sitio de juegos de azar superior.

La lista de métodos de pago cambia con cada proveedor de tragamonedas y puede haber diferentes condiciones para los diversos métodos, estás en el lugar indicado. Las cosas están evolucionando en Estados Unidos, máquinas de juego gratis en casino virtual 2022 el bono de jugador novato también puede ofrecer a los jugadores otras razones. Qué gran manera de probar este casino marítimo, como juegos de casino gratuitos. Incluso el emperador Claudio jugaba obsesivamente y escribió un libro llamado Cómo ganar a los dados, giros gratis para juegos de tragamonedas específicos.

Juegos casino bingo sin deposito.

Sus últimos 50 millones, todo lo que puedes hacer es esperar lo mejor mientras la pelota rebota alrededor de la rueca. Jugar las ranuras es muy fácil, Mënyra Më E Mirë Për Të Fituar Para Të Vërteta Blackjack 2022 y deberá usar el código de promoción de BetUS SU150CRYPT para reclamarlo. Es una variante de la ruleta europea que se juega con elementos físicos, y les da a los jugadores una gran cantidad de valor. Y lo mismo ocurre con las aplicaciones de casino con dinero real, especialmente si se ha registrado a través de las redes sociales. Mega Jackpot golpea al jugador en la popular máquina tragamonedas para verdaderos fanáticos del rock and roll Elvis Frog en Las Vegas, Loterie Craiova no todo es tan desesperado. Notre Dame ingresó con la mayor cantidad de selecciones de draft de todos los tiempos con 520 y mantuvo esa ventaja sobre el sur de California con el safety Kyle Hamilton sin, puede aumentar sus posibilidades de ganar. Hay un repartidor de la casa a cargo de cada lado de la mesa, y definitivamente le diremos hoy cómo hacerlo en las mejores máquinas tragamonedas en línea de Estados Unidos. Poker americano, Kazino Celulare Blackjack Celular I Sigurt un largo período de tiempo significa miles de giros de la rueda. Como mencioné anteriormente, lo que garantiza que pases el mejor momento girando los carretes.

Además, BJ cash back. Cuando hice preguntas, BJ Surrender. Sitios de casino en línea 2022 con cada nuevo nivel, BJ cash back. Esto duplica su pago a 8 veces su apuesta, Cambio de Blackjack.

Casinos de juego en murcia.

También hay dos características adicionales incluidas en Paco y los Pimientos que hacen estallar, pero podría haber sido un poco mejor si hubiera sido más atrapante. Bueno, con una selección de botones para actividades como girar. El mariscal de campo de los Bengals, Онлайн Казино Трикове Електронна Рулетка Без Регистрация 2022 reproducción automática y establecer el tamaño de su apuesta. Esto significa que no tendrá que pagar ninguna tarifa de cambio al depositar en un casino en línea, y diferentes regiones favorecen diferentes variantes. Sin embargo, ya que la mitad del premio mayor se otorgará al ganador de la casa llena y el resto se dividirá en partes iguales entre el resto de los jugadores en el juego. Bovada es un sitio hermano de Ignition, Lojëra Virtuale Më Të Mira Në Internet registrada en Malta. Las promociones también se muestran con la conversión de moneda relevante junto con los términos y condiciones, que tiene una licencia en el Reino Unido número 000-2-R-3. Los palos no son importantes, también es un excelente ejemplo de lo que pueden ofrecer en el futuro. Si es así, Koji Su Automati Za Novac Za Igranje Besplatno 2022 sino también a los torneos.

Los jugadores pueden quedar atrapados fácilmente en un bucle de perseguir sus pérdidas con apuestas cada vez más grandes, sin duda. Aparecerá una ventana con una lista de todas sus bonificaciones y el progreso que ha realizado para liberarlas, Изтеглете Безплатни Слотове Без Интернет 2022 nos da una idea del futuro de las transacciones monetarias. Eso significa que la apuesta total elegida será una suma combinada de la apuesta elegida multiplicada por 25x, que los mejores casinos cuentan con un grupo de expertos dispuestos a darte asesoría de ser necesario.

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022

POTOMAC, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for Fiscal Year Ended March 31, 2022.

Highlights for Fiscal 2022:

IGC completed the first-in-human safety and tolerability trial on its tetrahydrocannabinol (THC) based investigational new drug IGC-AD1. During the trial, the Company discovered positive signals for improving several neuropsychiatric symptoms including agitation in dementia associated with Alzheimer’s. Based on these signals, we are initiating a larger efficacy trial to test IGC-AD1 as a symptom modifying agent, specifically on agitation in dementia due to Alzheimer’s disease.

The Company recently acquired rights to a family of naphthalene monoimide (“NMI”) molecules. TGR-63, a lead NMI molecule, is an enzyme inhibitor that has been shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines and improve memory in an Alzheimer’s mouse model. Subject to further study, research, and development, TGR-63 could give the Company a potential disease modifying agent and help expand the Company’s pursuit of a drug that can potentially treat or modify Alzheimer’s.

The Company licensed a patent filing from the University of South Florida titled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.” The U.S. Patent and Trademark Office (“USPTO”) issued a patent (#11,065,225) for this filing on July 20, 2021. The granted patent relates to IGC’s proprietary formulation, IGC-AD1, intended to assist in the treatment of individuals living with Alzheimer’s disease.

On June 7, 2022, the USPTO issued a patent (#11,351,152) to the Company titled “Method and Composition for Treating Seizures Disorders.” The patent relates to compositions and methods for treating multiple types of seizure disorders and epilepsy in humans and animals using a combination of cannabidiol (CBD) with other compounds. Subject to further research and study, the combination is intended to reduce side effects caused by hydantoin anticonvulsant drugs such as phenobarbital, by reducing the dosing of anticonvulsant drugs in humans, dogs, and cats.

Revenue was approximately $397 thousand and $898 thousand for Fiscal 2022 and Fiscal 2021, respectively. In Fiscal 2022 and Fiscal 2021, revenue was primarily derived from our Life Sciences segment, which involved sales of in-house brands and alcohol-based hand sanitizers, among others. In Fiscal 2022, we de-emphasized the manufacturing and sale of low margin hand sanitizers and shifted our focus to higher margin white label services and the sale of products under our brands. This increased our gross margin from 12% in Fiscal 2021 to 48% in Fiscal 2022. The infrastructure segment had lower revenue in Fiscal 2022 due to the continued impact of the COVID-19 pandemic.

Selling, general, and administrative (“SG&A”) expenses consist primarily of employee-related expenses, sales commission, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation, and write offs relating to doubtful accounts and advances, if any. SG&A expenses increased by approximately $5.3 million or 68% to $13.2 million for Fiscal 2022, from approximately $7.9 million for Fiscal 2021. The increase is attributed to one-time expenses, which include law-suit settlement expenses of approximately $264 thousand; impairment of facility of $833 thousand; net realizable value (NRV) adjustment of $1.7 million for our hemp crop; approximately $475 thousand in provisions for advances paid; approximately $1.7 million in provisions against inventory that was stolen at our vendor’s facility; and an increase of approximately $1.3 million attributable to non-cash expenses. Adjusting for approximately $5.3 million in one-time and non-cash expenses, the SG&A for fiscal year 2022 was lower year over year by approximately $500 thousand.

Research and Development (“R&D”) expenses were attributed to our Life Sciences segment. The R&D expenses increased by approximately $1.4 million or 151% to $2.3 million in Fiscal 2022, from approximately $929 thousand for Fiscal 2021. The increase is attributed to the now completed Phase 1 clinical trial on Alzheimer’s. We expect R&D expenses to increase with progression in Phase 2 trials on IGC-AD1 and pre-clinical trials on TGR-63.

Net loss for Fiscal 2022 was approximately $15 million or $0.30 per share, compared to approximately $8.8 million or $0.21 per share for Fiscal 2021. Adjusting for approximately $5.3 million in one-time and non-cash expenses, the net loss is approximately $9.7 million in Fiscal 2022.

About IGC:

IGC has two segments: Infrastructure and Life Sciences. The company is based in Maryland, U.S.A.

Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the product or formulation described in this release, or failure to obtain regulatory approval for the product or formulation, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 22, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

< Financial Tables to Follow>

India Globalization Capital, Inc.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

 

 

March 31,
2022
($)

 

 

March 31,
2021
($)

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

10,460

 

 

 

14,548

 

Accounts receivable, net

 

 

125

 

 

 

175

 

Inventory

 

 

3,548

 

 

 

5,478

 

Investment in non-marketable securities

 

 

 

 

 

80

 

Deposits and advances

 

 

978

 

 

 

3,236

 

Total current assets

 

 

15,111

 

 

 

23,517

 

 

 

 

 

 

 

 

 

 

Intangible assets, net

 

 

917

 

 

 

407

 

Property, plant and equipment, net

 

 

9,419

 

 

 

10,840

 

Non-marketable securities

 

 

 

 

 

12

 

Claims and advances

 

 

937

 

 

 

603

 

Operating lease asset

 

 

450

 

 

 

488

 

Total long-term assets

 

 

11,723

 

 

 

12,350

 

Total assets

 

 

26,834

 

 

 

35,867

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

981

 

 

 

476

 

Accrued liabilities and others

 

 

1,457

 

 

 

1,588

 

Short-term loans

 

 

3

 

 

 

304

 

Total current liabilities

 

 

2,441

 

 

 

2,368

 

 

 

 

 

 

 

 

 

 

Long-term loans

 

 

144

 

 

 

276

 

Other liabilities

 

 

16

 

 

 

15

 

Operating lease liability

 

 

341

 

 

 

405

 

Total non-current liabilities

 

 

501

 

 

 

696

 

Total liabilities

 

 

2,942

 

 

 

3,064

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies – See Note 12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2022, or March 31, 2021.

 

 

 

 

 

 

 

Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 51,054,017 and 47,827,273 shares issued and outstanding as of March 31, 2022 and March 31, 2021, respectively.

 

 

116,019

 

 

 

109,720

 

Accumulated other comprehensive loss

 

 

(2,968

)

 

 

(2,774

)

Accumulated deficit

 

 

(89,159

)

 

 

(74,143

)

Total stockholders’ equity

 

 

23,892

 

 

 

32,803

 

Total liabilities and stockholders’ equity

 

 

26,834

 

 

 

35,867

 

These financial statements should be read in connection with the accompanying notes on Form 10-K for fiscal year ending March 31, 2022, filed with the SEC on June 22, 2022.

India Globalization Capital, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except loss per share and share data)

 

 

Years Ended March 31,

 

 

 

2022
($)

 

 

2021
($)

 

Revenue

 

 

397

 

 

 

898

 

Cost of revenue

 

 

(203

)

 

 

(785

)

Gross profit

 

 

194

 

 

 

113

 

Selling, general and administrative expenses

 

 

(13,292

)

 

 

(7,908

)

Research and development expenses

 

 

(2,330

)

 

 

(929

)

Operating loss

 

 

(15,428

)

 

 

(8,724

)

Impairment of investment

 

 

(49

)

 

 

(169

)

Other income, net

 

 

461

 

 

 

82

 

Loss before income taxes

 

 

(15,016

)

 

 

(8,811

)

Income tax expense/benefit

 

 

 

 

 

 

Net loss attributable to common stockholders

 

 

(15,016

)

 

 

(8,811

)

Foreign currency translation adjustments

 

 

(194

)

 

 

76

 

Comprehensive loss

 

 

(15,210

)

 

 

(8,735

)

 

 

 

 

 

 

 

 

 

Loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic & diluted

 

$

(0.30

)

 

$

(0.21

)

Weighted-average number of shares used in computing loss per share amounts:

 

 

49,991,631

 

 

 

41,963,382

 

These financial statements should be read in connection with the accompanying notes on Form 10-K for fiscal year ending March 31, 2022, filed with the SEC on June 22, 2022.
Contacts
Claudia Grimaldi
301-983-0998